Bach Pharma, Inc.
Bach Pharma is dedicated to advancing research and developing treatments for Gulf War Illness, neurodegenerative diseases, and other conditions affecting veterans and civilians. The company collaborates with government agencies, scientific institutions, and industry experts to bring innovative solutions to patients.
Industries
Nr. of Employees
small (1-50)
Bach Pharma, Inc.
North Andover, Massachusetts, United States, North America
Products
Small-molecule therapeutic candidate for neurological and veteran-related disorders
A small-molecule drug candidate developed for treatment of neurological dysfunction, including applications in Gulf War Illness and neurodegenerative disease, with reported studies addressing oxidative stress and brain function.
Small-molecule therapeutic candidate for neurological and veteran-related disorders
A small-molecule drug candidate developed for treatment of neurological dysfunction, including applications in Gulf War Illness and neurodegenerative disease, with reported studies addressing oxidative stress and brain function.
Services
Government and stakeholder collaboration
Coordination and collaboration with government agencies and veteran stakeholder groups for research and reporting related to therapeutic programs.
Scientific advisory and collaboration engagements
Engagement of external scientific advisors and research collaborators to support R&D programs.
Government and stakeholder collaboration
Coordination and collaboration with government agencies and veteran stakeholder groups for research and reporting related to therapeutic programs.
Scientific advisory and collaboration engagements
Engagement of external scientific advisors and research collaborators to support R&D programs.
Expertise Areas
- Veteran health and Gulf War Illness
- Neurodegenerative disease research (ALS)
- Oxidative stress–targeted therapeutics
- Preclinical and translational neurotherapeutics
Key Technologies
- Small-molecule therapeutic development
- Oxidative stress modulation
- Mechanism-of-action characterization
- Preclinical neurocognitive assessment